Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Pumosetrag Hydrochloride is an orally available 5-HT3 partial agonist. It is developed for the treatment of irritable bowel syndrome and gastroesophageal reflux disease.
Description | Pumosetrag Hydrochloride is an orally available 5-HT3 partial agonist. It is developed for the treatment of irritable bowel syndrome and gastroesophageal reflux disease. |
In vivo | Pumosetrag modulates gastrointestinal activity by delaying liquid gastric emptying through proximal stomach relaxation and enhancing fasting antroduodenal migrating motor complex activity, while also speeding up small intestinal transit. Its effectiveness varies across different sections of the mouse intestine, displaying minimal to no activity. This compound demonstrates regional and species-specific responses, with reduced efficacy compared to 5-HT in the rat's jejunum, ileum, and distal colon, yet showing comparable efficacy and potency in the rat's proximal colon. In contrast, Pumosetrag is more potent and effective than 5-HT across all regions of the guinea pig intestine. Its mechanism, mediated by 5-HT(3) receptors, is confirmed by the inhibitory effect of ondansetron on its actions in rat and guinea pig tissues. |
Synonyms | MKC-733, DDP-733 |
Molecular Weight | 339.84 |
Formula | C15H18ClN3O2S |
CAS No. | 194093-42-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 30 mg/mL (88.28 mM), Sonication and heating are recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Pumosetrag Hydrochloride 194093-42-0 GPCR/G Protein Neuroscience 5-HT Receptor DDP733 DDP 733 MKC 733 MKC-733 DDP-733 MKC733 inhibitor inhibit